ID   ARSB_HUMAN              Reviewed;         533 AA.
AC   P15848; B2RC20; Q9UDI9;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   22-FEB-2012, entry version 125.
DE   RecName: Full=Arylsulfatase B;
DE            Short=ASB;
DE            EC=3.1.6.12;
DE   AltName: Full=N-acetylgalactosamine-4-sulfatase;
DE            Short=G4S;
DE   Flags: Precursor;
GN   Name=ARSB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 103-119; 135-158;
RP   161-168; 286-295; 319-337; 379-387; 389-410; 440-450; 490-501; 508-520
RP   AND 525-533.
RC   TISSUE=Placenta, and Testis;
RX   MEDLINE=90153994; PubMed=2303452;
RA   Peters C., Schmidt B., Rommerskirch W., Rupp K., Zuehlsdorf M.,
RA   Vingron M., Meyer H.E., Pohlmann R., von Figura K.;
RT   "Phylogenetic conservation of arylsulfatases. cDNA cloning and
RT   expression of human arylsulfatase B.";
RL   J. Biol. Chem. 265:3374-3381(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=90152677; PubMed=1968043; DOI=10.1016/0888-7543(90)90460-C;
RA   Schuchman E.H., Jackson C.E., Desnick R.J.;
RT   "Human arylsulfatase B: MOPAC cloning, nucleotide sequence of a full-
RT   length cDNA, and regions of amino acid identity with arylsulfatases A
RT   and C.";
RL   Genomics 6:149-158(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT MET-358.
RX   MEDLINE=93332648; PubMed=7687847;
RA   Modaressi S., Rupp K., von Figura K., Peters C.;
RT   "Structure of the human arylsulfatase B gene.";
RL   Biol. Chem. Hoppe-Seyler 374:327-335(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT MET-358.
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-104.
RX   MEDLINE=92028992; PubMed=1930244;
RA   Litjens T., Morris C.P., Gibson G.J., Beckmann K.R., Hopwood J.J.;
RT   "Human N-acetylgalactosamine-4-sulphatase: protein maturation and
RT   isolation of genomic clones.";
RL   Biochem. Int. 24:209-215(1991).
RN   [6]
RP   PROTEIN SEQUENCE OF 41-55; 424-454 AND 466-483.
RC   TISSUE=Placenta;
RX   MEDLINE=93003385; PubMed=1390929; DOI=10.1016/0167-4838(92)90051-E;
RA   Kobayashi T., Honke K., Jin T., Gasa S., Miyazaki T., Makita A.;
RT   "Components and proteolytic processing sites of arylsulfatase B from
RT   human placenta.";
RL   Biochim. Biophys. Acta 1159:243-247(1992).
RN   [7]
RP   OXOALANINE AT CYS-91, MASS SPECTROMETRY, AND ABSENCE OF OXOALANINE IN
RP   MSD.
RX   MEDLINE=95354208; PubMed=7628016; DOI=10.1016/0092-8674(95)90314-3;
RA   Schmidt B., Selmer T., Ingendoh A., von Figura K.;
RT   "A novel amino acid modification in sulfatases that is defective in
RT   multiple sulfatase deficiency.";
RL   Cell 82:271-278(1995).
RN   [8]
RP   INVOLVEMENT IN MSD.
RX   PubMed=15146462; DOI=10.1002/humu.20040;
RA   Cosma M.P., Pepe S., Parenti G., Settembre C., Annunziata I.,
RA   Wade-Martins R., Domenico C.D., Natale P.D., Mankad A., Cox B.,
RA   Uziel G., Mancini G.M., Zammarchi E., Donati M.A., Kleijer W.J.,
RA   Filocamo M., Carrozzo R., Carella M., Ballabio A.;
RT   "Molecular and functional analysis of SUMF1 mutations in multiple
RT   sulfatase deficiency.";
RL   Hum. Mutat. 23:576-581(2004).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-366, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS).
RX   MEDLINE=97184692; PubMed=9032078; DOI=10.1016/S0969-2126(97)00185-8;
RA   Bond C.S., Clements P.R., Ashby S.J., Collyer C.A., Harrop S.J.,
RA   Hopwood J.J., Guss J.M.;
RT   "Structure of a human lysosomal sulfatase.";
RL   Structure 5:277-289(1997).
RN   [11]
RP   VARIANT MPS6 VAL-137, AND VARIANT MET-376.
RX   MEDLINE=92042029; PubMed=1718978;
RA   Wicker G., Prill V., Brooks D.A., Gibson G.J., Hopwood J.J.,
RA   von Figura K., Peters C.;
RT   "Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). An intermediate
RT   clinical phenotype caused by substitution of valine for glycine at
RT   position 137 of arylsulfatase B.";
RL   J. Biol. Chem. 266:21386-21391(1991).
RN   [12]
RP   VARIANTS MPS6 ARG-117; PRO-236 AND TYR-405.
RX   MEDLINE=92197625; PubMed=1550123;
RA   Jin W.-D., Jackson C.E., Desnick R.J., Schuchman E.H.;
RT   "Mucopolysaccharidosis type VI: identification of three mutations in
RT   the arylsulfatase B gene of patients with the severe and mild
RT   phenotypes provides molecular evidence for genetic heterogeneity.";
RL   Am. J. Hum. Genet. 50:795-800(1992).
RN   [13]
RP   VARIANTS MPS6 ARG-144; ARG-192; PRO-321 AND TYR-521, AND
RP   CHARACTERIZATION OF VARIANTS MPS6.
RX   MEDLINE=94160993; PubMed=8116615;
RA   Isbrandt D., Arlt G., Brooks D.A., Hopwood J.J., von Figura K.,
RA   Peters C.;
RT   "Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): six unique
RT   arylsulfatase B gene alleles causing variable disease phenotypes.";
RL   Am. J. Hum. Genet. 54:454-463(1994).
RN   [14]
RP   VARIANTS MPS6 TRP-152 AND GLN-160.
RX   MEDLINE=94171224; PubMed=8125475; DOI=10.1007/BF00212019;
RA   Voskoboeva E., Isbrandt D., von Figura K., Krasnopolskaya X.,
RA   Peters C.;
RT   "Four novel mutant alleles of the arylsulfatase B gene in two patients
RT   with intermediate form of mucopolysaccharidosis VI (Maroteaux-Lamy
RT   syndrome).";
RL   Hum. Genet. 93:259-264(1994).
RN   [15]
RP   VARIANTS MPS6 ILE-142; ARG-146; LEU-146 AND SER-146.
RX   MEDLINE=96125708; PubMed=8541342; DOI=10.1016/0925-4439(95)00070-4;
RA   Simonaro C.M., Schuchman E.H.;
RT   "N-acetylgalactosamine-4-sulfatase: identification of four new
RT   mutations within the conserved sulfatase region causing
RT   mucopolysaccharidosis type VI.";
RL   Biochim. Biophys. Acta 1272:129-132(1995).
RN   [16]
RP   VARIANTS MPS6 MET-92; GLN-95; CYS-210; PRO-393 AND PRO-498.
RX   MEDLINE=96213747; PubMed=8651289;
RA   Litjens T., Brooks D.A., Peters C., Gibson G.J., Hopwood J.J.;
RT   "Identification, expression, and biochemical characterization of N-
RT   acetylgalactosamine-4-sulfatase mutations and relationship with
RT   clinical phenotype in MPS6 patients.";
RL   Am. J. Hum. Genet. 58:1127-1134(1996).
RN   [17]
RP   VARIANT MPS-IV ARG-302.
RX   PubMed=10206678;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:5<410::AID-HUMU9>3.3.CO;2-H;
RA   Villani G.R.D., Balzano N., Di Natale P.;
RT   "Two novel mutations of the arylsulfatase B gene in two Italian
RT   patients with severe form of mucopolysaccharidosis.";
RL   Hum. Mutat. 11:410-410(1998).
RN   [18]
RP   VARIANT MET-358.
RX   MEDLINE=98248615; PubMed=9582121; DOI=10.1126/science.280.5366.1077;
RA   Wang D.G., Fan J.-B., Siao C.-J., Berno A., Young P., Sapolsky R.,
RA   Ghandour G., Perkins N., Winchester E., Spencer J., Kruglyak L.,
RA   Stein L., Hsie L., Topaloglou T., Hubbell E., Robinson E.,
RA   Mittmann M., Morris M.S., Shen N., Kilburn D., Rioux J., Nusbaum C.,
RA   Rozen S., Hudson T.J., Lipshutz R., Chee M., Lander E.S.;
RT   "Large-scale identification, mapping, and genotyping of single-
RT   nucleotide polymorphisms in the human genome.";
RL   Science 280:1077-1082(1998).
RN   [19]
RP   VARIANTS MPS6 PHE-65; HIS-116; GLN-315 AND ARG-531, AND VARIANT
RP   MET-358.
RX   MEDLINE=99156761; PubMed=10036316; DOI=10.1016/S0925-4439(98)00099-4;
RA   Villani G.R.D., Balzano N., Vitale D., Saviano M., Pavone V.,
RA   Di Natale P.;
RT   "Maroteaux-lamy syndrome: five novel mutations and their structural
RT   localization.";
RL   Biochim. Biophys. Acta 1453:185-192(1999).
RN   [20]
RP   VARIANTS MPS6 ARG-192 AND ARG-239.
RX   PubMed=10738004;
RX   DOI=10.1002/(SICI)1098-1004(200004)15:4<389::AID-HUMU31>3.0.CO;2-0;
RA   Wu J.-Y., Yang C.-F., Lee C.-C., Chang J.-G., Tsai F.-J.;
RT   "A novel mutation (Q239R) identified in a Taiwan Chinese patient with
RT   type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome).";
RL   Hum. Mutat. 15:389-390(2000).
RN   [21]
RP   VARIANTS MPS6 ARG-192; ARG-239 AND LEU-399, AND VARIANT MET-358.
RX   MEDLINE=21661185; PubMed=11802522;
RA   Yang C.-F., Wu J.-Y., Lin S.-P., Tsai F.-J.;
RT   "Mucopolysaccharidosis type VI: report of two Taiwanese patients and
RT   identification of one novel mutation.";
RL   J. Formos. Med. Assoc. 100:820-823(2001).
RN   [22]
RP   VARIANTS MPS6 TYR-86 DEL; CYS-210; PRO-236; CYS-312; GLN-315; PRO-321;
RP   ASN-384 AND GLY-484, VARIANTS MET-358 AND MET-376, AND
RP   CHARACTERIZATION OF VARIANTS MPS6 TYR-86 DEL AND CYS-312.
RX   PubMed=14974081; DOI=10.1002/humu.10313;
RA   Karageorgos L., Harmatz P., Simon J., Pollard A., Clements P.R.,
RA   Brooks D.A., Hopwood J.J.;
RT   "Mutational analysis of mucopolysaccharidosis type VI patients
RT   undergoing a trial of enzyme replacement therapy.";
RL   Hum. Mutat. 23:229-233(2004).
CC   -!- CATALYTIC ACTIVITY: Hydrolysis of the 4-sulfate groups of the N-
CC       acetyl-D-galactosamine 4-sulfate units of chondroitin sulfate and
CC       dermatan sulfate.
CC   -!- COFACTOR: Binds 1 calcium ion per subunit.
CC   -!- SUBUNIT: Monomer.
CC   -!- SUBCELLULAR LOCATION: Lysosome.
CC   -!- PTM: The conversion to 3-oxoalanine (also known as C-
CC       formylglycine, FGly), of a serine or cysteine residue in
CC       prokaryotes and of a cysteine residue in eukaryotes, is critical
CC       for catalytic activity. This post-translational modification is
CC       severely defective in multiple sulfatase deficiency (MSD).
CC   -!- DISEASE: Defects in ARSB are the cause of mucopolysaccharidosis
CC       type 6 (MPS6) [MIM:253200]; also known as Maroteaux-Lamy syndrome.
CC       MPS6 is an autosomal recessive lysosomal storage disease
CC       characterized by intracellular accumulation of dermatan sulfate.
CC       Clinical features can include abnormal growth, short stature,
CC       stiff joints, skeletal malformations, corneal clouding,
CC       hepatosplenomegaly, and cardiac abnormalities. A wide variation in
CC       clinical severity is observed.
CC   -!- DISEASE: Arylsulfatase B activity is defective in multiple
CC       sulfatase deficiency (MSD) [MIM:272200]. A clinically and
CC       biochemically heterogeneous disorder caused by the simultaneous
CC       impairment of all sulfatases, due to defective post-translational
CC       modification and activation. It combines features of individual
CC       sulfatase deficiencies such as metachromatic leukodystrophy,
CC       mucopolysaccharidosis, chondrodysplasia punctata, hydrocephalus,
CC       ichthyosis, neurologic deterioration and developmental delay.
CC       Note=Arylsulfatase B activity is impaired in multiple sulfatase
CC       deficiency due to mutations in SUMF1. SUMF1 mutations result in
CC       defective post-translational modification of ARSB at residue Cys-
CC       91 that is not converted to 3-oxoalanine.
CC   -!- SIMILARITY: Belongs to the sulfatase family.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/ARSB";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J05225; AAA51784.1; -; mRNA.
DR   EMBL; M32373; AAA51779.1; -; mRNA.
DR   EMBL; X72735; CAA51272.1; -; Genomic_DNA.
DR   EMBL; X72736; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72737; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72738; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72739; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72740; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72741; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; X72742; CAA51272.1; JOINED; Genomic_DNA.
DR   EMBL; AK314903; BAG37417.1; -; mRNA.
DR   EMBL; S57777; AAB19988.1; -; Genomic_DNA.
DR   IPI; IPI00306576; -.
DR   PIR; S35990; KJHUAB.
DR   RefSeq; NP_000037.2; NM_000046.3.
DR   UniGene; Hs.149103; -.
DR   UniGene; Hs.604199; -.
DR   PDB; 1FSU; X-ray; 2.50 A; A=42-533.
DR   PDBsum; 1FSU; -.
DR   ProteinModelPortal; P15848; -.
DR   SMR; P15848; 42-533.
DR   IntAct; P15848; 2.
DR   STRING; P15848; -.
DR   DMDM; 114223; -.
DR   PRIDE; P15848; -.
DR   Ensembl; ENST00000264914; ENSP00000264914; ENSG00000113273.
DR   Ensembl; ENST00000341088; ENSP00000342327; ENSG00000113273.
DR   GeneID; 411; -.
DR   KEGG; hsa:411; -.
DR   UCSC; uc003kfq.1; human.
DR   CTD; 411; -.
DR   GeneCards; GC05M078108; -.
DR   H-InvDB; HIX0018251; -.
DR   HGNC; HGNC:714; ARSB.
DR   HPA; HPA037770; -.
DR   HPA; HPA037771; -.
DR   MIM; 253200; phenotype.
DR   MIM; 272200; phenotype.
DR   MIM; 611542; gene.
DR   neXtProt; NX_P15848; -.
DR   Orphanet; 276212; Mucopolysaccharidosis type 6, rapidly progressing.
DR   Orphanet; 585; Multiple sulfatase deficiency.
DR   eggNOG; COG3119; -.
DR   GeneTree; ENSGT00560000077076; -.
DR   HOGENOM; HBG651618; -.
DR   HOVERGEN; HBG004282; -.
DR   InParanoid; P15848; -.
DR   KO; K01135; -.
DR   OMA; RHDLSRE; -.
DR   OrthoDB; EOG4DV5M0; -.
DR   PhylomeDB; P15848; -.
DR   BioCyc; MetaCyc:HS03665-MONOMER; -.
DR   BRENDA; 3.1.6.12; 2681.
DR   NextBio; 1737; -.
DR   ArrayExpress; P15848; -.
DR   Bgee; P15848; -.
DR   CleanEx; HS_ARSB; -.
DR   Genevestigator; P15848; -.
DR   GermOnline; ENSG00000113273; Homo sapiens.
DR   GO; GO:0005764; C:lysosome; TAS:ProtInc.
DR   GO; GO:0004065; F:arylsulfatase activity; TAS:ProtInc.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003943; F:N-acetylgalactosamine-4-sulfatase activity; IEA:EC.
DR   GO; GO:0007041; P:lysosomal transport; TAS:ProtInc.
DR   GO; GO:0007040; P:lysosome organization; TAS:ProtInc.
DR   InterPro; IPR017849; Alkaline_Pase-like_a/b/a.
DR   InterPro; IPR017850; Alkaline_phosphatase_core.
DR   InterPro; IPR000917; Sulfatase.
DR   InterPro; IPR024607; Sulfatase_CS.
DR   Gene3D; G3DSA:3.40.720.10; Alk_phosphtse; 1.
DR   Pfam; PF00884; Sulfatase; 1.
DR   SUPFAM; SSF53649; Alkaline_phosphatase_core; 1.
DR   PROSITE; PS00523; SULFATASE_1; 1.
DR   PROSITE; PS00149; SULFATASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Hydrolase; Ichthyosis;
KW   Leukodystrophy; Lysosome; Metachromatic leukodystrophy; Metal-binding;
KW   Mucopolysaccharidosis; Polymorphism; Reference proteome; Signal.
FT   SIGNAL        1     36       Or 38 (Potential).
FT   CHAIN        37    533       Arylsulfatase B.
FT                                /FTId=PRO_0000033421.
FT   ACT_SITE    147    147
FT   METAL        53     53       Calcium.
FT   METAL        54     54       Calcium.
FT   METAL        91     91       Calcium; via 3-oxoalanine.
FT   METAL       300    300       Calcium.
FT   METAL       301    301       Calcium.
FT   BINDING     145    145       Substrate (By similarity).
FT   BINDING     242    242       Substrate (By similarity).
FT   BINDING     318    318       Substrate (By similarity).
FT   MOD_RES      91     91       3-oxoalanine (Cys).
FT   CARBOHYD    188    188       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    279    279       N-linked (GlcNAc...).
FT   CARBOHYD    291    291       N-linked (GlcNAc...) (Probable).
FT   CARBOHYD    366    366       N-linked (GlcNAc...).
FT   CARBOHYD    426    426       N-linked (GlcNAc...).
FT   CARBOHYD    458    458       N-linked (GlcNAc...) (Potential).
FT   DISULFID    117    521
FT   DISULFID    121    155
FT   DISULFID    181    192
FT   DISULFID    405    447
FT   VARIANT      65     65       S -> F (in MPS6; intermediate form).
FT                                /FTId=VAR_019017.
FT   VARIANT      86     86       Missing (in MPS6; severe form; low
FT                                protein levels and activity).
FT                                /FTId=VAR_019018.
FT   VARIANT      92     92       T -> M (in MPS6; mild form).
FT                                /FTId=VAR_007294.
FT   VARIANT      95     95       R -> Q (in MPS6; mild/severe form).
FT                                /FTId=VAR_007295.
FT   VARIANT     116    116       P -> H (in MPS6; severe form).
FT                                /FTId=VAR_019019.
FT   VARIANT     117    117       C -> R (in MPS6; severe form).
FT                                /FTId=VAR_007296.
FT   VARIANT     137    137       G -> V (in MPS6; intermediate form).
FT                                /FTId=VAR_007297.
FT   VARIANT     142    142       M -> I (in MPS6).
FT                                /FTId=VAR_019020.
FT   VARIANT     144    144       G -> R (in MPS6; severe form; severe
FT                                reduction of activity).
FT                                /FTId=VAR_019021.
FT   VARIANT     146    146       W -> L (in MPS6).
FT                                /FTId=VAR_019022.
FT   VARIANT     146    146       W -> R (in MPS6).
FT                                /FTId=VAR_019023.
FT   VARIANT     146    146       W -> S (in MPS6).
FT                                /FTId=VAR_019024.
FT   VARIANT     152    152       R -> W (in MPS6; intermediate form).
FT                                /FTId=VAR_007298.
FT   VARIANT     160    160       R -> Q (in MPS6; intermediate form).
FT                                /FTId=VAR_007299.
FT   VARIANT     192    192       C -> R (in MPS6; mild form; severe
FT                                reduction of activity).
FT                                /FTId=VAR_019025.
FT   VARIANT     210    210       Y -> C (in MPS6; mild/intermediate).
FT                                /FTId=VAR_007300.
FT   VARIANT     236    236       L -> P (in MPS6; mild form).
FT                                /FTId=VAR_007301.
FT   VARIANT     239    239       Q -> R (in MPS6).
FT                                /FTId=VAR_019026.
FT   VARIANT     302    302       G -> R (in MPS6; severe form).
FT                                /FTId=VAR_007302.
FT   VARIANT     312    312       W -> C (in MPS6; severe form; low protein
FT                                levels and activity).
FT                                /FTId=VAR_019027.
FT   VARIANT     315    315       R -> Q (in MPS6; intermediate form).
FT                                /FTId=VAR_019028.
FT   VARIANT     321    321       L -> P (in MPS6; intermediate form;
FT                                severe reduction of activity).
FT                                /FTId=VAR_019029.
FT   VARIANT     358    358       V -> L (in dbSNP:rs1065757).
FT                                /FTId=VAR_061883.
FT   VARIANT     358    358       V -> M (in dbSNP:rs1065757).
FT                                /FTId=VAR_016061.
FT   VARIANT     376    376       V -> M (in dbSNP:rs17220759).
FT                                /FTId=VAR_007303.
FT   VARIANT     384    384       S -> N (in MPS6; dbSNP:rs25414).
FT                                /FTId=VAR_019030.
FT   VARIANT     393    393       H -> P (in MPS6; mild/severe form).
FT                                /FTId=VAR_007304.
FT   VARIANT     399    399       F -> L (in MPS6).
FT                                /FTId=VAR_019031.
FT   VARIANT     405    405       C -> Y (in MPS6; mild form).
FT                                /FTId=VAR_007305.
FT   VARIANT     484    484       R -> G (in MPS6).
FT                                /FTId=VAR_019032.
FT   VARIANT     498    498       L -> P (in MPS6; mild/severe form).
FT                                /FTId=VAR_007306.
FT   VARIANT     521    521       C -> Y (in MPS6; severe form; severe
FT                                reduction of activity).
FT                                /FTId=VAR_019033.
FT   VARIANT     531    531       P -> R (in MPS6; mild form).
FT                                /FTId=VAR_019034.
FT   CONFLICT    153    153       K -> F (in Ref. 1; AA sequence).
FT   CONFLICT    408    410       NSM -> SPC (in Ref. 1; AA sequence).
FT   STRAND       46     54
FT   HELIX        61     63
FT   HELIX        70     77
FT   STRAND       79     82
FT   HELIX        93    100
FT   HELIX       104    107
FT   HELIX       129    135
FT   STRAND      139    144
FT   HELIX       153    155
FT   HELIX       157    159
FT   STRAND      163    167
FT   STRAND      169    171
FT   TURN        175    177
FT   STRAND      179    184
FT   TURN        185    188
FT   STRAND      189    194
FT   HELIX       211    224
FT   STRAND      232    237
FT   STRAND      242    244
FT   HELIX       249    251
FT   HELIX       253    255
FT   HELIX       261    286
FT   HELIX       290    292
FT   STRAND      293    301
FT   HELIX       305    307
FT   STRAND      320    322
FT   HELIX       323    326
FT   STRAND      330    333
FT   STRAND      341    344
FT   HELIX       350    352
FT   HELIX       353    360
FT   HELIX       377    382
FT   STRAND      390    396
FT   STRAND      429    435
FT   STRAND      438    443
FT   TURN        454    456
FT   STRAND      472    476
FT   TURN        477    479
FT   TURN        488    490
FT   HELIX       492    507
FT   HELIX       519    521
FT   TURN        524    526
SQ   SEQUENCE   533 AA;  59687 MW;  5983FB6911C4789A CRC64;
     MGPRGAASLP RGPGPRRLLL PVVLPLLLLL LLAPPGSGAG ASRPPHLVFL LADDLGWNDV
     GFHGSRIRTP HLDALAAGGV LLDNYYTQPL CTPSRSQLLT GRYQIRTGLQ HQIIWPCQPS
     CVPLDEKLLP QLLKEAGYTT HMVGKWHLGM YRKECLPTRR GFDTYFGYLL GSEDYYSHER
     CTLIDALNVT RCALDFRDGE EVATGYKNMY STNIFTKRAI ALITNHPPEK PLFLYLALQS
     VHEPLQVPEE YLKPYDFIQD KNRHHYAGMV SLMDEAVGNV TAALKSSGLW NNTVFIFSTD
     NGGQTLAGGN NWPLRGRKWS LWEGGVRGVG FVASPLLKQK GVKNRELIHI SDWLPTLVKL
     ARGHTNGTKP LDGFDVWKTI SEGSPSPRIE LLHNIDPNFV DSSPCPRNSM APAKDDSSLP
     EYSAFNTSVH AAIRHGNWKL LTGYPGCGYW FPPPSQYNVS EIPSSDPPTK TLWLFDIDRD
     PEERHDLSRE YPHIVTKLLS RLQFYHKHSV PVYFPAQDPR CDPKATGVWG PWM
//
